Related Experiment Video
Updated: Jan 8, 2026
Therapeutic Evaluation of Fecal Microbiota Transplantation in an Interleukin 10-Deficient Mouse Model
Published on: April 6, 2022
Ancient grain flour consumption as a novel therapeutic approach for irritable bowel syndrome
Samantha Maurotti1, Yvelise Ferro2, Elisa Mazza3
1Department of Clinical and Experimental Medicine, University "Magna Græcia" of Catanzaro, 88100, Catanzaro, Italy.
Background:
Climate change has revived interest in ancient grains for their sustainability and nutritional value. Less processed and more resilient than modern cereals, they have a lower environmental impact. Grains like Triticum monococcum and Jermano wheat may benefit IBS patients due to their better digestibility. This study explores their use in functional pasta to manage IBS symptoms.
Methods:
Forty-two IBS patients followed a 4-week low-FODMAP diet with either traditional gluten-free pasta or functional pasta (FP) made from emmer and rye flour. IBS symptoms were assessed using the IBS-SSS questionnaire at baseline and after intervention. In vitro, functional pasta extract (FPE) was tested on TNF-α-induced Caco-2 and T84 cells to evaluate its effects on inflammatory and oxidative stress markers.
Results:
Patients consuming FP showed a significant reduction in IBS-SSS scores compared to the control group (- 153 ± 124 vs. - 83 ± 85, p = 0.044). Additionally, 83% of those on FP reported a clinically significant reduction in symptom severity (IBS-SSS score ≥ 100) compared to 35% in the control group (p = 0.004). In Caco-2 and T84 cells, FPE has been shown to downregulate protein expression of the pErk1/2 and NF-κB signaling pathways, thereby reducing inflammatory oxidative stress markers.
Conclusion:
These findings suggest that consuming functional pasta made with ancient grains could enhance gut health and alleviate symptoms of IBS by reducing inflammation and oxidative stress. This innovative dietary approach offers a promising natural alternative for improving the quality of life in IBS patients.
Trial Registration:
Trial registration ISRCTN, ISRCTN12170245 Registered 13 june 2025-Retrospectively Registered, https://doi.org/10.1186/ISRCTN12170245 .
More Related Videos
08:58Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis
Published on: January 5, 2017
08:34Investigating the Alleviating Effects of Bacillus cereus Administration on Colitis through Gut Microbiota Modulation
Published on: July 27, 2022
Related Concept Videos
01:30Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
01:30Irritable Bowel Syndrome III: Medical and Nursing Management
01:17Irritable Bowel Syndrome I: Introduction
IBS is a chronic condition that can persist over a long period or recur frequently.
The pathogenesis of IBS involves a complex interplay of the following factors:
Altered...
01:17Drugs for Treatment of Diarrhea-Predominant IBS
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
01:21Drugs for Treatment of Constipation-Predominant IBS
01:30Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation
Irritable Bowel Syndrome (IBS) is classified into subtypes based on the predominant bowel habits as determined by the Bristol Stool Form Scale (BSFS). The subtypes are: